This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

21 Jun 2018

Patch-in-a-Can technology to delivery pain management product

MedPharm licenses its MedSpray ‘Patch-in-a-Can’ technology to Virpax Pharmaceuticals.

MedPharm has licensed its unique MedSpray technology to Virpax Pharmaceuticals, a company that specialises in developing pharmaceutical products for pain management by using new drug delivery systems. MedSpray is covered by worldwide patents and delivers transdermal patch technology in a metered-dose aerosol spray. The thin film patch created on the skin or mucosal membrane has been demonstrated in clinical trials to provide long-lasting efficacy for patients.

MedPharm is working closely with Virpax to develop DSF100 (NSAID spray film 1.3%), an investigational spray film designed to deliver an NSAID transdermally via a metered-dose spray. The delivery system features a high level of adhesiveness, accessibility and skin drying. Virpax filed a pre-IND meeting request with the FDA and it was granted on 18 May 2018.

“MedSpray’s unique dosing offers clients the opportunity to differentiate their product and potentially achieve premium pricing for extended effects,” said Dr Jeremy Drummond, MedPharm’s SVP of Business Development. “We are looking forward to partnering with Virpax to bring products with our MedSpray technology to market.”

“We believe there is an opportunity to explore the development of non-opioid transdermal pain treatments that improve on existing gel and patch products, for which adhesion and accessibility can be a challenge,” said Anthony Mack, CEO of Virpax. “We believe that the ‘Patch-in-a-Can’ technology offers a promising delivery system and we are excited to be collaborating with a world leader like MedPharm.”

During the last 20 years, MedPharm has built a worldwide reputation for helping clients navigate the complex route to successful development of its pharmaceutical products. In parallel with fees for service work, MedPharm is constantly looking for opportunities to develop new formulation and drug delivery technologies such as MedSpray, which enhances clients’ products, provides clinical benefits for patients and meets the increasingly stringent requirements of regulatory authorities.

Related News